Cogent Biosciences

Cogent Biosciences

Who We Are
 

Cogent Biosciences is a publicly traded biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Positive results from registration-directed trials in NonAdvanced SM, Advanced SM and GIST were reported in 2025. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα, KRAS and JAK2.

 
Our Team
 

 

Departments (8)
Offices (3)
2
open positions
1
hiring across
0
last 24 hours
0
remote listings
2  positions
Cogent Biosciences
Desktop and Field Sales Support Specialist
Cogent Biosciences
Waltham, Massachusetts,... IT 3w ago
Cogent Biosciences
Director, IT Business Partner
Cogent Biosciences
Waltham, Massachusetts,... IT 1mo ago

Pick a job to read the details

Tap any role on the left — its description and apply link will open here.